Compare REX AI Equity Premium Income ETF (AIPI) vs Smith & Nephew plc (SNN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Smith & Nephew plc — how do they compare? REX AI Equity Premium Income ETF trades at $36.35, while Smith & Nephew plc trades at $30.02 (market cap $12.73B). The key difference: Smith & Nephew plc pays a 2.57% dividend while REX AI Equity Premium Income ETF pays none, and REX AI Equity Premium Income ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| AIPI | SNN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $38.70 |
52-Week Low | $32.45 | $28.73 |
Market Cap | — | $12.73B |
Enterprise Value | — | $15.50B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
Smith & Nephew (SNN) trades at $30.48, up 0.76% with a bullish technical signal. The company shows improving fundamentals with revenue growing from $5.8B in 2024 to $6.2B in 2025 and net income margin expanding to 10.13%. Recent product launches in robotics and wound care demonstrate innovation momentum. Technical indicators show support at $30 and resistance at $31, with moving averages signaling bullish momentum.
SNN presents a mixed investment case with strong revenue growth and margin expansion offset by inconsistent earnings performance. The company's $500M share buyback and positive 2026 outlook provide support, but recent earnings misses and cautious analyst sentiment (68% hold rating) suggest near-term caution. Key risks include execution challenges and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
